Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 rilzabrutinib versus placebo in persistent or chronic immune thrombocytopenia
NL-OMON53830Phase 3Completed
- Sponsor
- Principia Biopharma
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rilzabrutinib in immune thrombocytopenia (ITP) (3 arms), sponsored by Principia Biopharma. Primary endpoint: Durable platelet response. Started Aug 2023; status: completed.
02
Drugs
rilzabrutinib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NL-OMON53830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53830.